A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer

Sponsor
Hoffmann-La Roche
Study ID
NCT02595450
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
35 Years - 86 Years
Healthy Volunteers
Not accepted

Interventions

  • Erlotinib — DRUG
    Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.

Study Details

This is a non-interventional, open label, single arm, multicenter study to assess the safety and efficacy of erlotinib in participants with non-small cell lung cancer.

Key Dates

First listed
Nov 3, 2015
Start date
Sep 30, 2008
Status verified
Dec 2015
Primary completion
Nov 30, 2014
Completion
Nov 30, 2014

Study Design

Enrollment
299 participants (actual)

Arms

  • Arm: Erlotinib
    Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.

Primary Outcome Measure

Progression-free Survival (PFS) Time [ Time Frame: Up to 6 years ]

Related Studies